Mass spectrometric quantification of asparagine synthetase in circulating leukemia cells from acute lymphoblastic leukemia patients.

The appearance of asparaginase-resistant acute lymphoblastic leukemia (ALL) in transformed cell lines has been correlated with increased expression of asparagine synthetase (ASNS). Recent measurements using mRNA-based assays have raised doubts, however, as to the importance of ASNS protein in the cellular mechanisms that confer drug resistance upon the leukemic cells. Studies aimed at determining the concentration of ASNS protein in human leukemias are therefore needed to resolve this issue. A mass spectrometry (MS)-based procedure is presented for the direct quantification of ASNS protein concentration in complex sample mixtures. This assay is able to distinguish samples from transformed cell lines that express ASNS over a wide dynamic range of concentration. Importantly, this method directly detects ASNS protein, the functional entity that may be synthesizing sufficient asparagine to render leukemia cells resistant to asparaginase-treatment. We also report the successful use of this MS method, which has lower limits of detection and quantification of 30 and 100 attomoles, respectively, for the first direct measurements of ASNS protein concentrations in four patient blast samples.

[1]  L L Needham,et al.  Isotope dilution--mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. , 1996, Clinical chemistry.

[2]  A. Hall,et al.  Expression levels of asparagine synthetase in blasts from children and adults with acute lymphoblastic leukaemia , 2006, British journal of haematology.

[3]  D. Voehringer,et al.  L-asparaginase kills lymphoma cells by apoptosis , 2004, Cancer Chemotherapy and Pharmacology.

[4]  J. Boos,et al.  The best way to use asparaginase in childhood acute lymphatic leukaemia – still to be defined? , 2004, British journal of haematology.

[5]  S. Heys,et al.  Measurement of albumin synthesis in humans: a new approach employing stable isotopes. , 1990, The American journal of physiology.

[6]  H. Mikawa,et al.  Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. , 1989, Leukemia.

[7]  S. Schuster,et al.  Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. , 1997, American Journal of Physiology.

[8]  O. Hrusak,et al.  Upregulation of asparagine synthetase fails to avert cell cycle arrest induced by L-asparaginase in TEL/AML1-positive leukaemic cells , 2004, Leukemia.

[9]  Constance J Jeffery,et al.  Mass spectrometry and the search for moonlighting proteins. , 2005, Mass spectrometry reviews.

[10]  E. Estlin,et al.  Remission induction therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of vincristine, corticosteroids, L-asparaginase and anthracyclines. , 2001, Cancer treatment reviews.

[11]  M. Amylon,et al.  Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study , 1999, Leukemia.

[12]  M. D. Den Boer,et al.  Up-regulation of asparagine synthetase expression is not linked to the clinical response L-asparaginase in pediatric acute lymphoblastic leukemia. , 2006, Blood.

[13]  T. Ueno,et al.  Cell cycle arrest and apoptosis of leukemia cells induced by L-asparaginase , 1997, Leukemia.

[14]  C. Schaefer,et al.  Quantitative proteomic analysis of inorganic phosphate‐induced murine MC3T3‐E1 osteoblast cells , 2004, Electrophoresis.

[15]  R. Yost,et al.  Triple quadrupole mass spectrometry for direct mixture analysis and structure elucidation. , 1979, Analytical chemistry.

[16]  S. Gygi,et al.  Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[17]  C. Haskell,et al.  l-asparaginase resistance in human leukemia--asparagine synthetase. , 1969, Biochemical pharmacology.

[18]  Nigel G J Richards,et al.  Asparagine synthetase chemotherapy. , 2006, Annual review of biochemistry.

[19]  L. Boxer,et al.  A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia. , 2005, Cancer research.

[20]  R. Handschumacher,et al.  L-asparaginase and L-asparagine metabolism. , 1970, Annual review of pharmacology.

[21]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[22]  M. Kilberg,et al.  Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. , 2001, The Biochemical journal.

[23]  R. Aebersold,et al.  Mass spectrometry in proteomics. , 2001, Chemical reviews.

[24]  F. McLafferty.  Tandem mass spectrometry. , 1981, Science.

[25]  Nigel G. J. Richards,et al.  Mechanistic issues in asparagine synthetase catalysis. , 1998, Advances in enzymology and related areas of molecular biology.

[26]  R. Pieters,et al.  Asparagine synthetase activity in paediatric acute leukaemias: AML‐M5 subtype shows lowest activity , 2000, British journal of haematology.

[27]  Werner Zolg,et al.  Quantification of C‐reactive protein in the serum of patients with rheumatoid arthritis using multiple reaction monitoring mass spectrometry and 13C‐labeled peptide standards , 2004, Proteomics.

[28]  F. J. Holler,et al.  Principles of Instrumental Analysis , 1973 .

[29]  Y. Ravindranath.  Recent advances in pediatric acute lymphoblastic and myeloid leukemia , 2003, Current opinion in oncology.

[30]  W. Evans,et al.  Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. , 2005, Blood.

[31]  M. D. Den Boer,et al.  Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. , 2003, Blood.

[32]  Pui,et al.  Childhood Acute Lymphoblastic Leukemia. , 1997, The oncologist.

[33]  R. Barr,et al.  Management of Children with Acute Lymphoblastic Leukemia by the Dana‐Farber Cancer Institute Protocols: An Update of the Ontario Experience , 1992, The American journal of pediatric hematology/oncology.

[34]  Gabriel S. Eichler,et al.  Asparagine synthetase as a causal, predictive biomarker for l-asparaginase activity in ovarian cancer cells , 2006, Molecular Cancer Therapeutics.

[35]  Susan E. Abbatiello,et al.  Efficient expression, purification, and characterization of C-terminally tagged, recombinant human asparagine synthetase. , 2005, Archives of biochemistry and biophysics.

[36]  Edward A. Dratz,et al.  Absolute quantification of the G protein-coupled receptor rhodopsin by LC/MS/MS using proteolysis product peptides and synthetic peptide standards. , 2003 .

[37]  A Wlodawer,et al.  Structural basis for the activity and substrate specificity of Erwinia chrysanthemi L-asparaginase. , 2001, Biochemistry.

[38]  G. Gustafsson,et al.  Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation , 2000, Leukemia.

[39]  Patrik Edén,et al.  Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  G. Hurteau,et al.  Accurate detection of Asparagine Synthetase (ASNS) using quantitative real-time PCR (qRT-PCR), without requiring DNaseI treatment , 2005, Leukemia.

[41]  S. Gygi,et al.  Correlation between Protein and mRNA Abundance in Yeast , 1999, Molecular and Cellular Biology.

[42]  R. Gelber,et al.  Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. , 1983, Cancer research.